Synopsis of recent research by authors named "Roland Buelow"
- Roland Buelow's recent research primarily focuses on the development of innovative immunotherapeutic strategies, particularly bispecific antibodies and T-cell engagers aimed at selectively targeting cancer cells while minimizing on-target, off-tumor toxicities.
- His studies have demonstrated the potential of these engineered antibodies, such as the TNB-928B and TNB-738, to enhance immune responses against tumors and boost intracellular NAD+ levels by inhibiting CD38, with promising applications in treating ovarian cancer and various B-cell malignancies.
- Additionally, Buelow's work on transgenic animals for antibody production underscores the importance of developing models that facilitate the generation of high-affinity human antibodies, contributing to more effective therapeutic options and a better understanding of immune responses in diseases like pulmonary hypertension.
